title: Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates.
abstract: OBJECTIVE
  To assess the effect of pretreatment with an oral contraceptive (OC) on ovarian cyst formation during pituitary suppression with buserelin acetate.
  
  
  METHODS
  Prospective randomized trial.
  
  
  METHODS
  Academic medical center.
  
  
  METHODS
  Eighty-three patients who were undergoing IVF-ET treatment.
  
  
  METHODS
  Patients in the study group were pretreated with an OC for 14 days starting on the first day of menstruation. The administration of SC buserelin acetate was initiated on the last day of OC administration. Patients in the control group began to receive buserelin acetate on day 2 of menstruation. Hormonal assays and ultrasound scans were performed on the first day of menstruation, and 7, 11, and 14 days after the commencement of buserelin acetate administration. Thereafter, these tests were performed weekly until pituitary suppression was achieved.
  
  
  METHODS
  Incidence of cyst formation.
  
  
  RESULTS
  A cyst developed in 27 patients in the control group (52.9%) and no patients in the study group (odds ratio [OR]=115; 95% confidence interval [CI]=10-617). Patients in the study group achieved pituitary suppression faster (median difference [MD]=7 days; 95% CI=4-14) and required fewer ampules of gonadotropin (MD=10; 95% CI=6-14). They recruited more follicles (MD=3; 95% CI=0-5) and had higher pregnancy rates (37.2% versus 33.3%).
  
  
  CONCLUSIONS
  Pretreatment with an OC abolishes ovarian cyst formation, shortens the time required to achieve pituitary suppression, and decreases gonadotropin requirements without having a negative effect on pregnancy rates.
authors.affiliation: McGill Reproductive Center, Department of Obstetrics and Gynecology, Royal Victoria Hospital, McGill University, Montreal, Quebec, Canada.
authors.forename: M M
authors.initials: MM
authors.lastname: Biljan
authors.forename: N G
authors.initials: NG
authors.lastname: Mahutte
authors.forename: N
authors.initials: N
authors.lastname: Dean
authors.forename: R
authors.initials: R
authors.lastname: Hemmings
authors.forename: F
authors.initials: F
authors.lastname: Bissonnette
authors.forename: S L
authors.initials: SL
authors.lastname: Tan
mesh_terms: D000328:Adult; D002064:Buserelin / Q000627:therapeutic use*; D003276:Contraceptives, Oral / Q000627:therapeutic use*; D003864:Depression, Chemical; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D010064:Embryo Implantation; D004624:Embryo Transfer; D005260:Female; D005307:Fertilization in Vitro; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D010048:Ovarian Cysts / Q000139:chemically induced / Q000000981:diagnostic imaging / Q000453:epidemiology; D006080:Ovarian Follicle / Q000187:drug effects; D010902:Pituitary Gland / Q000187:drug effects*; D011247:Pregnancy; D018873:Pregnancy Rate; D011446:Prospective Studies; D014463:Ultrasonography
chemical_list: D003276:Contraceptives, Oral; D007987:Gonadotropin-Releasing Hormone; D002064:Buserelin